Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt No Debt
NBIX's Cash-to-Debt is ranked higher than
99% of the 733 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.95 vs. NBIX: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NBIX' s Cash-to-Debt Range Over the Past 10 Years
Min: 3.4  Med: 49 Max: No Debt
Current: No Debt
Interest Coverage No Debt
NBIX's Interest Coverage is ranked higher than
98% of the 721 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 88.12 vs. NBIX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NBIX' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: No Debt
N/A
No Debt
Piotroski F-Score: 3
Altman Z-Score: 39.34
Beneish M-Score: -3.79
WACC vs ROIC
15.39%
-963.54%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -982.48
NBIX's Operating Margin % is ranked lower than
94% of the 686 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.19 vs. NBIX: -982.48 )
Ranked among companies with meaningful Operating Margin % only.
NBIX' s Operating Margin % Range Over the Past 10 Years
Min: -17340.03  Med: -982.48 Max: 43.82
Current: -982.48
-17340.03
43.82
Net Margin % -940.60
NBIX's Net Margin % is ranked lower than
94% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. NBIX: -940.60 )
Ranked among companies with meaningful Net Margin % only.
NBIX' s Net Margin % Range Over the Past 10 Years
Min: -16936.19  Med: -940.6 Max: 48.53
Current: -940.6
-16936.19
48.53
ROE % -37.42
NBIX's ROE % is ranked lower than
84% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.86 vs. NBIX: -37.42 )
Ranked among companies with meaningful ROE % only.
NBIX' s ROE % Range Over the Past 10 Years
Min: -250.63  Med: -37.48 Max: 94.61
Current: -37.42
-250.63
94.61
ROA % -33.15
NBIX's ROA % is ranked lower than
85% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.38 vs. NBIX: -33.15 )
Ranked among companies with meaningful ROA % only.
NBIX' s ROA % Range Over the Past 10 Years
Min: -62.22  Med: -28.37 Max: 26.57
Current: -33.15
-62.22
26.57
ROC (Joel Greenblatt) % -2879.37
NBIX's ROC (Joel Greenblatt) % is ranked lower than
93% of the 724 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.39 vs. NBIX: -2879.37 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NBIX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3172.32  Med: -928.61 Max: 2175.88
Current: -2879.37
-3172.32
2175.88
3-Year Revenue Growth Rate 57.80
NBIX's 3-Year Revenue Growth Rate is ranked higher than
96% of the 604 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.70 vs. NBIX: 57.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NBIX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -100  Med: -12.4 Max: 170.6
Current: 57.8
-100
170.6
3-Year EBITDA Growth Rate 32.00
NBIX's 3-Year EBITDA Growth Rate is ranked higher than
81% of the 577 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.20 vs. NBIX: 32.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NBIX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -64.3  Med: 31.05 Max: 109.6
Current: 32
-64.3
109.6
3-Year EPS without NRI Growth Rate 33.20
NBIX's 3-Year EPS without NRI Growth Rate is ranked higher than
81% of the 548 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. NBIX: 33.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NBIX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -69.8  Med: 21.05 Max: 66.3
Current: 33.2
-69.8
66.3
GuruFocus has detected 3 Warning Signs with Neurocrine Biosciences Inc $NBIX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NBIX's 10-Y Financials

Financials (Next Earnings Date: 2017-05-14 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

NBIX Guru Trades in Q1 2016

George Soros 9,400 sh (New)
Pioneer Investments 193,026 sh (+1.88%)
Louis Moore Bacon Sold Out
RS Investment Management 11,090 sh (-98.18%)
» More
Q2 2016

NBIX Guru Trades in Q2 2016

RS Investment Management 11,090 sh (unchged)
George Soros Sold Out
Pioneer Investments 158,001 sh (-18.15%)
» More
Q3 2016

NBIX Guru Trades in Q3 2016

George Soros 11,322 sh (New)
Jana Partners 96,210 sh (New)
Pioneer Investments 157,165 sh (-0.53%)
» More
Q4 2016

NBIX Guru Trades in Q4 2016

Jana Partners 181,296 sh (+88.44%)
George Soros Sold Out
Pioneer Investments 153,347 sh (-2.43%)
» More
» Details

Insider Trades

Latest Guru Trades with NBIX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325414    SIC: 2836
Compare:NYSE:VRX » details
Traded in other countries:NB3.Germany,
Neurocrine Biosciences Inc discovers, develops and commercializes drugs for the treatment of neurological and endocrine-related diseases and disorders.

Neurocrine Biosciences is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company has yet to launch a product and continues to accumulate significant operating losses. A now-canceled commercialization agreement with Pfizer accounted for 94% of revenue between 2003 and 2005 in the form of reimbursements and milestone payments.

Guru Investment Theses on Neurocrine Biosciences Inc

Meridian Funds Comments on Neurocrine Biosciences - Aug 31, 2015

Neurocrine Biosciences (NASDAQ:NBIX) is a pharmaceutical company with two development-stage programs focused on neurological and endocrine-based health problems. The company came to our attention after poor clinical trial results for one of its programs resulted in a 40% reduction in the share price. We invested because the issues with the trial were related to trial design, not drug efficacy. Management presented a credible plan for addressing the design issues, and the company’s valuation was capturing only a fraction of the potential cash flows that could be generated by both drug programs. Over the past year, both of Neurocrine’s drug programs have delivered strong clinical trial results and are on track for commercialization, which may drive significant earnings and cash flow growth. We have reduced our position somewhat over the past year due to the strong appreciation in share price but continue to hold shares in Neurocrine Biosciences.



From Meridian Growth Fund’s annual letter.



Check out Meridian Funds latest stock trades

Ratios

vs
industry
vs
history
PB Ratio 11.51
NBIX's PB Ratio is ranked lower than
92% of the 898 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.82 vs. NBIX: 11.51 )
Ranked among companies with meaningful PB Ratio only.
NBIX' s PB Ratio Range Over the Past 10 Years
Min: 0.9  Med: 6.3 Max: 120
Current: 11.51
0.9
120
PS Ratio 240.71
NBIX's PS Ratio is ranked lower than
97% of the 867 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.76 vs. NBIX: 240.71 )
Ranked among companies with meaningful PS Ratio only.
NBIX' s PS Ratio Range Over the Past 10 Years
Min: 3.16  Med: 37.26 Max: 3581.82
Current: 240.71
3.16
3581.82
Current Ratio 10.21
NBIX's Current Ratio is ranked higher than
92% of the 629 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.38 vs. NBIX: 10.21 )
Ranked among companies with meaningful Current Ratio only.
NBIX' s Current Ratio Range Over the Past 10 Years
Min: 2.52  Med: 9.92 Max: 14.94
Current: 10.21
2.52
14.94
Quick Ratio 10.21
NBIX's Quick Ratio is ranked higher than
94% of the 628 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.75 vs. NBIX: 10.21 )
Ranked among companies with meaningful Quick Ratio only.
NBIX' s Quick Ratio Range Over the Past 10 Years
Min: 2.52  Med: 9.92 Max: 14.94
Current: 10.21
2.52
14.94

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -8.90
NBIX's 3-Year Average Share Buyback Ratio is ranked lower than
67% of the 446 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.00 vs. NBIX: -8.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NBIX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -17  Med: -9.1 Max: -1.3
Current: -8.9
-17
-1.3

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 14.07
NBIX's Price-to-Net-Cash is ranked lower than
57% of the 268 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.85 vs. NBIX: 14.07 )
Ranked among companies with meaningful Price-to-Net-Cash only.
NBIX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 3.67  Med: 8.68 Max: 254.67
Current: 14.07
3.67
254.67
Price-to-Net-Current-Asset-Value 13.88
NBIX's Price-to-Net-Current-Asset-Value is ranked lower than
73% of the 615 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.44 vs. NBIX: 13.88 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
NBIX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.06  Med: 6.67 Max: 50.93
Current: 13.88
2.06
50.93
Price-to-Tangible-Book 11.50
NBIX's Price-to-Tangible-Book is ranked lower than
86% of the 830 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.52 vs. NBIX: 11.50 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
NBIX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.26  Med: 5.19 Max: 30.22
Current: 11.5
1.26
30.22
Price-to-Median-PS-Value 6.46
NBIX's Price-to-Median-PS-Value is ranked lower than
97% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.18 vs. NBIX: 6.46 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NBIX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.15  Med: 0.75 Max: 6.57
Current: 6.46
0.15
6.57
Earnings Yield (Greenblatt) % -4.44
NBIX's Earnings Yield (Greenblatt) % is ranked lower than
77% of the 1021 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.62 vs. NBIX: -4.44 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NBIX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -4.45  Med: 8.6 Max: 3139.3
Current: -4.44
-4.45
3139.3

More Statistics

Revenue (TTM) (Mil) $15.00
EPS (TTM) $ -1.63
Beta1.73
Short Percentage of Float5.70%
52-Week Range $33.56 - 55.15
Shares Outstanding (Mil)87.11

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 45 179 338
EPS ($) -2.20 -1.42 -0.26
EPS without NRI ($) -2.20 -1.42 -0.26
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NBIX

Headlines

Articles On GuruFocus.com
AbbVie: Encouraging Results From Elagolix Study Oct 20 2016 
Meridian Funds Comments on Neurocrine Biosciences Aug 31 2015 
Meridian Contrarian Fund Annual Report 2015 Aug 31 2015 
Weekly Insider Sells Highlight: ORCL, TWC, FB, NBIX Jan 13 2014 
5 Strong Healthcare Stocks For 2012 Mar 24 2012 
Consider These 5 Healthcare Stocks Now Mar 21 2012 
Neurocrine Biosciences Inc. (NBIX) VP and CFO Timothy P Coughlin sells 12,320 Shares Mar 02 2011 
Neurocrine Biosciences Inc. (NBIX) President and CEO Kevin Charles Gorman sells 15,400 Shares Mar 02 2011 
Neurocrine Biosciences Inc. Reports Operating Results (10-Q) Oct 29 2010 
Neurocrine Biosciences Inc. Reports Operating Results (10-Q) Jul 29 2010 

More From Other Websites
Setting The Stage For Neurocrine's Pending PDUFA Date, Barclays Remains Positive Mar 24 2017
Neurocrine Announces American Journal of Psychiatry Publication of Positive Results from Kinect 3... Mar 21 2017
NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Other Events Mar 13 2017
NEUROCRINE BIOSCIENCES INC Financials Feb 18 2017
Neurocrine Biosciences, Inc. :NBIX-US: Earnings Analysis: 2016 By the Numbers : February 16, 2017 Feb 16 2017
NBIX: Acquires North American Rights to ONGENTYS® For the Treatment of Parkinson’s Disease Feb 16 2017
[2/15] Today's Top 10 Long/Short Estimize Signal Scores Feb 15 2017
Edited Transcript of NBIX earnings conference call or presentation 14-Feb-17 10:00pm GMT Feb 14 2017
NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 14 2017
Neurocrine reports 4Q loss Feb 14 2017
Neurocrine reports 4Q loss Feb 14 2017
Neurocrine Biosciences Reports Year-End 2016 Results and Provides Investor Update for 2017 Feb 14 2017
Q4 2016 Neurocrine Biosciences Inc Earnings Release - After Market Close Feb 14 2017
NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in... Feb 10 2017
Neurocrine Inks $145 Million Parkinson's Drug Deal Feb 10 2017
Neurocrine and BIAL Announce Exclusive North American Licensing Agreement for Opicapone Feb 09 2017
Neurocrine Biosciences Announces Conference Call and Webcast to Report Fourth Quarter and Year-End... Feb 07 2017
[2/7] Today's Top 10 Long/Short Estimize Signal Scores Feb 07 2017
Neurocrine Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : NBIX-US :... Feb 01 2017
Premarket Biotech Movers: Neurocrine Biosciences, Aralez Pharmaceuticals, Qiagen Jan 27 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)